Browsing Tag
Phase 2a trial
2 posts
Why oncology clinicians are watching EOM613’s effect on muscle loss, appetite, and chemotherapy readiness
Find out how EOM613 could reshape cancer cachexia treatment as EOM Pharmaceutical Holdings advances its FDA-cleared Phase 2a study.
Sanofi signs $1.45bn deal to acquire Kymab, expanding its immune-therapy pipeline
In a significant move to bolster its immuno-oncology and immune-mediated disease portfolio, Sanofi has acquired Kymab, a UK-based…